[사회]Is there a domestic COVID-19 treatment?…Celltrion “reduces the severity by 54%”

[사회]Is there a domestic COVID-19 treatment?…Celltrion “reduces the severity by 54%”

by

Korean Corona 19 antibody treatment’Rekironaju’ Phase 2 data released
The effect of reducing the recovery period of corona patients
It seems difficult to expect treatment effects for severely ill patients

[앵커]

The results of phase 2 clinical trials of’Rekironaju’, Korea’s first COVID-19 antibody treatment, came out.

In patients with less severe symptoms, it prevented the condition from worsening and shortened the recovery period, but treatment effects have not been proven for severely ill patients.

Reporter Shin Hyun-jun.

[기자]

It is the Corona 19 antibody treatment’Rekironaju’ being developed by the domestic pharmaceutical company Celltrion.

Data on phase 2 clinical trials of this treatment in more than 300 mild and moderate patients have been released.

The incidence of severe patients decreased by 54% in all patients and 68% in people in their 50s and older when Rekirona was administered.

This means that if you give this drug to mild or moderately ill patients at the beginning of the confirmed corona19, you can reduce the severity of worsening by more than half.

In addition, it has also been shown to reduce the recovery period for corona patients.

The period for the disappearance of corona symptoms such as fever or cough was shortened by more than 3 days to 5.4 days for the Rekirona group and 8.8 days for the sham drug group.

In particular, patients in their 50s and older with moderate illness reduced the recovery period by more than 5-6 days.

None of the subjects in the clinical trials had serious adverse reactions or died.

However, experts say that it is difficult to expect treatment effects for severely ill patients.

To date, foreign-made remdesivir is the only COVID-19 treatment approved in Korea.

[김상봉 / 식품의약품안전처 바이오생약국장 : (렉키로나주는) 코로나19 바이러스의 표면에 있는 인체 세포 결합 부위에 항체 치료제가 대신 결합함으로써 바이러스가 세포 내로 침투되는 것을 막게 됩니다.]

The Ministry of Food and Drug Safety is planning to approve the drug first on the condition that the clinical results of the phase 3 are submitted later when the stability and effectiveness of this treatment are confirmed.

YTN Shin Hyun-jun[[email protected]]is.

※’Your report becomes news’ YTN is waiting for your valuable report.
[카카오톡] Search YTN to add a channel [전화] 02-398-8585 [메일] [email protected] [온라인 제보] www.ytn.co.kr

[저작권자(c) YTN & YTN plus 무단전재 및 재배포 금지]

.Source